Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017

Ongoing Management Decisions in Soft Tissue Sarcoma

November 14th 2017

Multidisciplinary Team in Soft Tissue Sarcoma

November 14th 2017

How Sarcoma Experts Work With Community Oncologists

November 14th 2017

Histopathological Diagnosis in Soft Tissue Sarcoma

November 14th 2017

Heterogeneity of Soft Tissue Sarcomas

November 14th 2017

Follicular Lymphoma: Audience Q&A

October 21st 2017

Follicular Lymphoma: Complexities in Combinations

October 21st 2017

Follicular Lymphoma: Considering All Novel Agents

October 21st 2017

FL: The Impact of Data from Clinical Trials

October 21st 2017

Follicular Lymphoma: Challenges in Moving Forward

October 21st 2017

Follicular Lymphoma: Optimizing Copanlisib

October 21st 2017

Follicular Lymphoma: Defining Copanlisib

October 21st 2017

Follicular Lymphoma: Overview of Treatment Options

October 21st 2017

Follicular Lymphoma: Outcomes with Immunotherapy

October 21st 2017

Early Study Shows Promise for Genetically Modified TILs in Advanced Melanoma

October 20th 2017

Treatment with genetically engineered tumor infiltrating lymphocytes showed some signs of activity and very little added toxicity for patients with metastatic melanoma.

Expert Discusses Mutations in Melanoma

October 19th 2017

Alan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.

Dr. Zandberg on Biomarker Development in Head and Neck Cancer

October 18th 2017

Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib

October 17th 2017

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses resistance mechanisms that occur in patients with EGFR-positive T790M non

MET/EGFR Combo Effective for Advanced NSCLC

October 17th 2017

The combination of osimertinib and the MET inhibitor savolitinib showed signs of efficacy for pretreated patients with MET-positive, EGFR-mutant non–small cell lung cancer.